The UK based CDMO, eXmoor pharma and UK based engineered T-regulatory cell therapy developer, Quell Therapeutics, have entered into an agreement under which eXmoor pharma will provide manufacturing support through development of Quell Therapeutics’ cell therapy candidates.

Under the terms of the multi-year agreement, Quell and eXmoor will partner on the process transfer, scale-out and Phase 1/2 clinical manufacture of multiple autologous CAR-Treg cell therapy candidates in Quell’s pipeline, with eXmoor to dedicate manufacturing capacity within its new Cell & Gene Therapy Centre in Bristol, UK.